Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Control, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation From Living CMV-Seropositive Donors (D+)

Trial Profile

A Randomized, Placebo-Control, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation From Living CMV-Seropositive Donors (D+)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2019

At a glance

  • Drugs HB 101 (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; Pharmacodynamics; Proof of concept
  • Sponsors Hookipa Pharma
  • Most Recent Events

    • 27 Dec 2018 Planned End Date changed from 1 Aug 2020 to 15 Jan 2021.
    • 27 Dec 2018 Planned primary completion date changed from 1 Sep 2019 to 15 Jan 2021.
    • 17 Dec 2018 According to a Hookipa Pharma medis release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top